HIVACAR aims to provide a new therapeutic alternative to “cART for life” (combined antiretroviral therapy) and will address the individual and public health limitations associated with this standard of care:
- Cost of the medication.
- Mandatory high adherence to medication for life.
- Side effects.
- Risk of resistances developement.
An innovative strategy based on the patient’s immune system, safe, affordable and scalable to achieve the functional cure of HIV-1 infection will be tested in a Phase I / IIa clinical trial. In addition, the ethical, economic and psychosocial challenges associated with a functional HIV cure will be investigated to provide a complementary alternative to the current treatment standard.
The HIVACAR project is developed with the contribution of representatives of the community of people living with HIV in Europe. The European AIDS Treatment Group (EATG) is a partner of the HIVACAR consortium and is responsible for: assessing, from the participants’...
Currently, over 36 million people worldwide are infected with HIV, most of them living in developing countries1. In 2014, 1.2 million people died of AIDS-related illnesses…